Please note that maintenance work is scheduled between 4 AM and 5 AM - CET.
During this time, you may experience reduced performance.
Thanks for your patience.
in (world ranking)
Patrick Vermersch
Neurology — Centre Hospitalier Universitaire de Lille, France
Patrick Vermersch
Joined May 2024
Centre Hospitalier Universitaire de Lille · Neurology
Top 1% Worldwide expert in Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Autoimmune Diseases
A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis 2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis
Phase 3
Active not recruiting
2024
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis followed by long term treatment with remibrutinib 2023-509372-41-00 — sclerosis, multiple sclerosis, safety, therapeutics
Phase 3
Active not recruiting
2022
A Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Treatment in Patients with Multiple Sclerosis Previously Enrolled in a Genentech and or F Hoffmann La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program 2023-507633-21-01 — sclerosis, multiple sclerosis, therapeutics
Phase 3
Not yet recruiting
2024
LONG TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS CONSONANCE EXTENSION STUDY 2024-516433-13-00 — safety
Phase 3
Recruiting
2024
A Rollover Study to Evaluate the Long Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis 2023-505974-14-00 — sclerosis, multiple sclerosis, safety
To provide the best experience, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawal of consent may adversely affect certain features and functions.
Functional
Always active
Storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of transmitting a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
Storage or technical access used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles in order to send advertisements, or to track the user on a website or on several websites with similar marketing purposes.